Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party
Standard
Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party. / Penack, Olaf; Peczynski, Christophe; Koenecke, Christian; Polge, Emmanuelle; Sanderson, Robin; Yakoub-Agha, Ibrahim; Fegueux, Nathalie; Daskalakis, Michael; Collin, Matthew; Dreger, Peter; Kröger, Nicolaus; Schanz, Urs; Bloor, Adrian; Ganser, Arnold; Besley, Caroline; Wulf, Gerald G; Novak, Urban; Moiseev, Ivan; Schoemans, Hélène; Basak, Grzegorz W; Chabannon, Christian; Sureda, Anna; Glass, Bertram; Peric, Zinaida.
in: FRONT IMMUNOL, Jahrgang 14, 2023, S. 1252811.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party
AU - Penack, Olaf
AU - Peczynski, Christophe
AU - Koenecke, Christian
AU - Polge, Emmanuelle
AU - Sanderson, Robin
AU - Yakoub-Agha, Ibrahim
AU - Fegueux, Nathalie
AU - Daskalakis, Michael
AU - Collin, Matthew
AU - Dreger, Peter
AU - Kröger, Nicolaus
AU - Schanz, Urs
AU - Bloor, Adrian
AU - Ganser, Arnold
AU - Besley, Caroline
AU - Wulf, Gerald G
AU - Novak, Urban
AU - Moiseev, Ivan
AU - Schoemans, Hélène
AU - Basak, Grzegorz W
AU - Chabannon, Christian
AU - Sureda, Anna
AU - Glass, Bertram
AU - Peric, Zinaida
N1 - Copyright © 2023 Penack, Peczynski, Koenecke, Polge, Sanderson, Yakoub-Agha, Fegueux, Daskalakis, Collin, Dreger, Kröger, Schanz, Bloor, Ganser, Besley, Wulf, Novak, Moiseev, Schoemans, Basak, Chabannon, Sureda, Glass and Peric.
PY - 2023
Y1 - 2023
N2 - We investigated ≥ grade 3 (CTC-AE) organ toxicities for commercial CD19 chimeric antigen receptor T cell (CAR-T cell) products in 492 patients (Axi-Cel; n = 315; Tisa-Cel; n = 177) with Large B-cell Lymphoma in the European Society for Blood and Marrow Transplantation (EBMT) CAR-T registry. The incidence of ≥ grade 3 organ toxicities during the first 100 days after CAR-T was low and the most frequent were: renal (3.0%), cardiac (2.3%), gastro-intestinal (2.3%) and hepatic (1.8%). The majority occurred within three weeks after CAR-T cell therapy. Overall survival was 83.1% [79.8-86.5; 95% CI] at 3 months and 53.5% [49-58.4; 95% CI] at one year after CAR-T. The most frequent cause of death was tumour progression (85.1%). Non-relapse mortality was 3.1% [2.3-4.1; 95% CI] at 3 months and 5.2% [4.1-6.5; 95% CI] at one year after CAR-T. The most frequent causes of non-relapse mortality were cell-therapy-related toxicities including organ toxicities (6.4% of total deaths) and infections (4.4% of total deaths). Our data demonstrates good safety in the European real-world setting.
AB - We investigated ≥ grade 3 (CTC-AE) organ toxicities for commercial CD19 chimeric antigen receptor T cell (CAR-T cell) products in 492 patients (Axi-Cel; n = 315; Tisa-Cel; n = 177) with Large B-cell Lymphoma in the European Society for Blood and Marrow Transplantation (EBMT) CAR-T registry. The incidence of ≥ grade 3 organ toxicities during the first 100 days after CAR-T was low and the most frequent were: renal (3.0%), cardiac (2.3%), gastro-intestinal (2.3%) and hepatic (1.8%). The majority occurred within three weeks after CAR-T cell therapy. Overall survival was 83.1% [79.8-86.5; 95% CI] at 3 months and 53.5% [49-58.4; 95% CI] at one year after CAR-T. The most frequent cause of death was tumour progression (85.1%). Non-relapse mortality was 3.1% [2.3-4.1; 95% CI] at 3 months and 5.2% [4.1-6.5; 95% CI] at one year after CAR-T. The most frequent causes of non-relapse mortality were cell-therapy-related toxicities including organ toxicities (6.4% of total deaths) and infections (4.4% of total deaths). Our data demonstrates good safety in the European real-world setting.
KW - Humans
KW - Immunotherapy, Adoptive/adverse effects
KW - Retrospective Studies
KW - Receptors, Chimeric Antigen
KW - Lymphoma, Large B-Cell, Diffuse/etiology
KW - Adaptor Proteins, Signal Transducing
KW - Antigens, CD19
U2 - 10.3389/fimmu.2023.1252811
DO - 10.3389/fimmu.2023.1252811
M3 - SCORING: Journal article
C2 - 37828980
VL - 14
SP - 1252811
JO - FRONT IMMUNOL
JF - FRONT IMMUNOL
SN - 1664-3224
ER -